Across TCGA pan-cancer cohorts, SPATA42 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated SPATA42 data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SPATA42 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA42 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCS show a favorable association.
KIRC, UCEC, and LIHC are the cancer types where SPATA42 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.